Premium
Human papillomavirus infection in lung and esophageal cancers: Analysis of 485 Asian cases
Author(s) -
Goto Akiteru,
Li ChihPing,
Ota Satoshi,
Niki Toshiro,
Ohtsuki Yuji,
Kitajima Shinichi,
Yonezawa Suguru,
Koriyama Chihaya,
Akiba Suminori,
Uchima Hisataka,
Lin YuehMin,
Yeh KunTu,
Koh JaeSoo,
Kim ChulWoo,
Kwon KunYong,
Nga Min En,
Fukayama Masashi
Publication year - 2011
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.22150
Subject(s) - lung cancer , adenocarcinoma , medicine , lung , carcinoma , esophageal cancer , hpv infection , cervical cancer , oncology , cancer , pathology
The role of human papillomavirus (HPV) in the development of lung and esophageal cancer remains inconclusive, which is in contrast to the established role HPV plays in the development of uterine cervical cancer. One of the reasons for this is the difference among reported HPV infection rates in these cancers. An analysis of 485 lung and esophageal cancers (176 lung squamous cell carcinoma, 128 lung adenocarcinoma, 181 esophageal carcinoma) in eight institutions in Asia (Tokyo, Kochi, Kagoshima, and Okinawa, Japan; Seoul and Daegu, Korea; Changhua, Republic of China (Taiwan); Singapore, Singapore) was carried out in order to clarify infection rates with HPV. Samples were examined in one laboratory of the Department of Pathology, the University of Tokyo, Japan in order to avoid inter‐laboratory variation using a combination of polymerase chain reaction and in situ hybridization (ISH). HPV was found in 6.3%, 7%, and 9.4% of patients with lung squamous cell carcinoma, lung adenocarcinoma, and esophageal cancer, respectively. Among the geographic areas surveyed, Kagoshima exhibited a significantly higher prevalence of HPV infection in cases of esophageal carcinoma (24.1%). There was no geographical difference in the infection rates of HPV in lung carcinomas. Subtype‐specific ISH was also performed, which identified the high‐risk HPV types 16/18 in the majority (75.7%) of the patients with lung and esophageal cancer positive for HPV. J. Med. Virol. 83:1383–1390, 2011. © 2011 Wiley‐Liss, Inc.